MerTK drives anti-PD-1/PD-L1 resistance in hepatocellular carcinoma by limiting ferroptosis and promoting an immunosuppressive microenvironment, with its inhibition by sitravatinib enhancing therapy efficacy. The gene discussed is MERTK; the disease is hepatocellular carcinoma.